Marlena Paździor-Heiske

Dr. Marlena Paździor-Heiske

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2020 in Energies
Verified
Journal Article
Open access
PDF file
Józef CiułaJózef Ciuła
Józef Ciuła
VKVioletta Kozik
Violetta Kozik
Agnieszka GenerowiczAgnieszka Generowicz
Agnieszka Generowicz
Krzysztof GaskaKrzysztof Gaska
Krzysztof Gaska
ABAndrzej Bak
Andrzej Bak
Krzysztof BarbusińskiKrzysztof Barbusiński
Krzysztof Barbusiński
An attempt was made to estimate the annual production of CH4 at a municipal waste landfill site in Poland. As a matter of fact, the extent of the unorganized emission of CH4 from the landfill surface was approached based on the adopted mathematical model. The Ward agglomeration method for cluster analysis and the Pearson coefficient were employed to evaluate the distance-based similarity measure and to optimize methods for estimating methane emissions from a landfill as well as to verify the input parameters for the model. In order to calculate the content of biodegradable organic parts in the waste, morphological tests of the landfilled waste were performed. Physical quantities, measurements and the actual amount of the landfilled waste as well as the volume of CH4 neutralized in a collective flare were implemented in the model, respectively. The model-based findings and experimental outcome demonstrated stable gas production in the landfill with a high CH4 content. On the other hand, a rather low efficiency of the landfill passive degassing installation indicated the necessity to design and develop its active counterpart with the prospective application of the generated biogas for energy production in a cogeneration system.

Verified
Journal Article
Open access
PDF file
VKVioletta Kozik
Violetta Kozik
DPDanuta Pentak
Danuta Pentak
MPMarlena Paździor-Heiske
Marlena Paździor-Heiske
AZAndrzej Zięba
Andrzej Zięba
ABAndrzej Bak
Andrzej Bak
The marketed drug Doxorubicin (DOX) and the promising anti-cancer agent 9-(N-piperazinyl)-5-methyl-12(H)-quino[3,4-b][1,4]benzothiazinium chloride (9-PBThACl) were used to prepare and compare a range of liposomal delivery systems based on dipalmitoylphosphatidylcholine (DPPC). Liposome-assisted drug release was examined using the spectrophotometric method. In order to provide in vitro release characteristics of liposomal conjugates (LDPPC/drug vs. LDPPC/drug/drug) as well as to evaluate the impact of temperature and pH buffering on the conformation/polarity of the phospholipid bilayer, the encapsulation efficiency of the liposomes entrapping 9-PBThACl and DOX was calculated. In fact, some competition between the investigated molecules was noticed during the entrapment process because relatively high values of the encapsulation efficiency were observed only for the liposomal complexes containing one trapped drug molecule. An averaged absorbance value enabled us to indicate the pH value of the environment (pH ≈ 6.8), at which the physicochemical property profiles of the liposomal complexes were noticeably changed. Moreover, the operational factors limiting the drug release kinetics from the produced liposomes were mathematically modeled. First-order and Bhaskas models ensured satisfactory compliance with the experimental data for the liposomal complexes buffered at pH values of 5.50, 6.00, and 7.40, respectively.

Verified
Journal Article
Open access
PDF file
RSRobert Sarna
Robert Sarna
Robert KubinaRobert Kubina
Robert Kubina
MPMarlena Paździor-Heiske
Marlena Paździor-Heiske
AHAdrianna Halama
Adrianna Halama
PCPatryk Chudy
Patryk Chudy
INIlona Nowak
Ilona Nowak
Head and neck squamous cell carcinomas (HNSCCs) represent a heterogeneous group of tumors with a complex molecular profile. Despite therapeutic advances, patient prognosis remains poor, emphasizing the need for more effective treatment strategies. Traditional chemotherapy, with cisplatin and 5-fluorouracil (5-FU), remains the gold standard but is limited by toxicity and tumor resistance. Immunotherapy, particularly immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and its ligand (PD-L1), has improved overall survival, especially in patients with high PD-L1 expression. In parallel, targeted therapies such as poly (ADP-ribose) polymerase 1 (PARP1) inhibitors—which impair DNA repair and increase replication stress—have shown promising activity in HNSCC. Cyclin-dependent kinase (CDK) inhibitors are also under investigation due to their potential to correct dysregulated cell cycle control, a hallmark of HNSCC. This review aims to summarize current and emerging pharmacotherapies for HNSCC, focusing on chemotherapy, immunotherapy, and PARP and CDK inhibitors. It also discusses the evolving role of targeted therapies in improving clinical outcomes. Future research directions include combination therapies, nanotechnology-based delivery systems to enhance treatment specificity, and the development of diagnostic tools such as PARP1-targeted imaging to better guide personalized treatment approaches.

6 February 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DPDanuta Pentak
Danuta Pentak
VKVioletta Kozik
Violetta Kozik
AZAndrzej Zięba
Andrzej Zięba
MPMarlena Paździor-Heiske
Marlena Paździor-Heiske
ASAleksandra Szymczyk
Aleksandra Szymczyk
ABAndrzej Bak
Andrzej Bak
Background/Objectives: The principal aim of this work was to prepare a liposomal drug delivery system based on the commercial drug doxorubicin (DOX) and a budding agent with promising anticancer activity, 9-(N-piperazinyl)-5-methyl-12(H)-quino [3,4-b][1,4]benzothiazinium chloride (9-PBThACl). Methods: A spectrophotometric methodology was used to meticulously investigate the drug entrapment and release characteristics of the new liposomal complexes (L) based on dipalmitoylphosphatidylcholine (DPPC) with human serum albumin (HSA) and its defeated analog (dHSA). Results: The impact of the operational parameters (temperature and pH) on the liposome/drug(s)/(d)HSA, namely [LDPPC/9-PBThACl/DOX ]:(d)HSA] systems, as well as the polarity of the phospholipid bilayer, was examined. In order to compare the experimental findings, mathematical models were employed to specify the analytical factors controlling the process of drug release/potential drug release from liposomes. The observed variations in the drug encapsulation and release profiles were due to the combination of liposomal conjugates with human plasma protein. Conclusions: It was proven that changes in the environmental pH directly affect the percentage of drug entrapment in liposomes and the medicine release efficiency. Moreover, the grouping tendency of the liposomal combinations was investigated using a principal component analysis (PCA) and a hierarchical clustering analysis (HCA). Finally, an analysis of variance (ANOVA) confirmed the statistical impact of pH buffering and changing temperature factors on the drug release characteristics of liposomal conjugates.

Verified
Journal Article
Open access
PDF file
INIlona Nowak
Ilona Nowak
MPMarlena Paździor-Heiske
Marlena Paździor-Heiske
RSRobert Sarna
Robert Sarna
MMMarcel Madej
Marcel Madej
Neurodegenerative diseases are a diverse group of diseases characterized by a progressive loss of neurological function due to damage to nerve cells in the central nervous system. In recent years, there has been a worldwide increase in the expanding associated with increasing human life expectancy. Molecular mechanisms control many of the essential life processes of cells, such as replication, transcription, translation, protein synthesis and gene regulation. These are complex interactions that form the basis for understanding numerous processes in the organism and developing new diagnostic and therapeutic approaches. In the context of neurodegenerative diseases, molecular basis refers to changes at the molecular level that cause damage to or degeneration of nerve cells. These may include protein aggregates leading to pathological structures in brain cells, impaired protein transport in nerve cells, mitochondrial dysfunction, inflammatory processes or genetic mutations that impair nerve cell function. New medical therapies are based on these mechanisms and include gene therapies, reduction in inflammation and oxidative stress, and the use of miRNAs and regenerative medicine. The aim of this study was to bring together the current state of knowledge regarding selected neurodegenerative diseases, presenting the underlying molecular mechanisms involved, which could be potential targets for new forms of treatment.